[B030] 医药文献

{
  "data": {
    "doi": "10.1007/s00262-011-1007-5",
    "drug": [
      {
        "drug_id": "e82b83b42eba4e5ea3f26f8e06081a5a",
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ]
      }
    ],
    "author": [
      "Karen Angélica Cavassani",
      "Maria Renata Sales Nogueira Costa",
      "Thaís Helena Gasparoto"
    ],
    "source": [
      "CROSSREF",
      "PUBMED",
      "CAS",
      "MAG"
    ],
    "target": [
      {
        "target_id": "1c2067e5ab054a8995f73efcfcf56207",
        "short_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ]
      }
    ],
    "disease": [
      {
        "disease_id": "06a9082fe1ec4c97bea31d888b9cfdce",
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ]
      }
    ],
    "journal": "Cancer Immunology, Immunotherapy",
    "paper_id": "c61f84d1-b6b6-35d8-b178-94faa296df56",
    "epub_date": 20110327,
    "paper_title": [
      {
        "lang": "EN",
        "title": "Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials"
      }
    ],
    "organization": [
      {
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "organization_id": "87bfaf037f8e60c9e25595cd98bb27e4"
      }
    ],
    "paper_abstract": [
      {
        "abst": "PD-1 and PD-L1 can be involved in tumor escape, and little is known about the role of these molecules in oral tumors or pre-malignant lesions. In the present study, we investigated the expression of PD-1 and PD-L1 in the blood and lesion samples of patients with actinic cheilitis (AC) and oral squamous cell carcinoma (OSCC). Our results showed that lymphocytes from peripheral blood and tissue samples exhibited high expression of PD-1 in both groups analyzed. Patients with AC presented higher percentage as well as the absolute numbers of CD4+PD-1+ and CD8+PD-1+ lymphocytes in peripheral blood mononuclear cells (PBMC) than healthy individuals, while patients with OSCC presented an increased frequency of CD8+PD1+ in PBMC when compared with controls. On the other hand, increased frequency of CD4+ and CD8+ T cells expressing PD-1(+) accumulate in samples from OSCC, and the expression of PD-L1 was intense in OSCC and moderate in AC lesion sites. Lower levels of IFN-γ and higher levels of TGF-β were detected in OSCC samples. Our data demonstrate that PD-1 and PD-L1 molecules are present in blood and samples of AC and OSCC patients. Further studies are required to understand the significance of PD-1 and PD-L1 in oral tumors microenvironment.",
        "lang": "EN"
      }
    ],
    "publication_date": 20110701
  },
  "status": true,
  "error_code": 0
}